SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZTC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (659)2/4/2000 4:14:00 PM
From: Vector1  Read Replies (2) of 752
 
GZTC was actually priced to go up 20%. What has been happening is that if an offering is substantially oversubscribed (10-1 today is typical)the underwriters will get verbal commitments from the buyers that they will continue to buy in the aftermarket. If they do not make the commitment they do not get an alocation in the offering. We will likely see the same thing with Celgene which is pricing a follow on in a few weeks. That deal will be massively oversubscribed and the smart money is buying in now in anticipation.

What is truly great about the GZTC offering is that it allows GZTC to get out from the shadow of its parent and for the first time is properly capitalized which will give them much better leverage in negotiating deals with pharma. Quite a while ago you asked for picks that had 100 to 1 potential. GZTC was one of my picks. The stock was at 4 at the time so I still have quite a way to go. Thankfully we are beyond that dastardly floorless convert.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News